MedWatch

Weight loss as new diabetes target could boost sales of Novo Nordisk's obesity drug

Lasting weight loss should be the primary treatment target for people with type 2 diabetes, according to several researchers. Novo Nordisk, which has recently launched Wegovy, a drug that can lead to weight loss of up to 17 percent on average, agrees with the assessment.

Photo: Jens Dresling/Ritzau Scanpix

Wallets at Novo Nordisk might get fatter if enduring weight loss becomes the primary treatment goal for people with type 2 diabetes, as several researchers have proposed in the Lancet, Danish business daily Børsen reports on Wednesday.

A person with type 2 diabetes who loses 15 percent of their bodyweight could see disease-altering effects, and the drugs Saxenda and the more recently launched Wegovy from Novo Nordisk are excelling in their ability to reduce bodyweight in obese patients by over 15 percent over a longer period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs